- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03460899
Impact of Hypoglycaemia in Patients With Diabetes Mellitus Type 2 on Platelet Activation (Diaplate)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Increased platelet activation is significantly involved in the pathophysiology of micro- and macrovascular diabetic complications. Previously performed studies suggested platelet activation in both, hyper- and hypoglycaemic states, leading to a potentially increased risk for thromboembolic complications. Hypoglycaemia, in particular severe hypoglycaemic episodes, has been associated with increased cardiovascular or overall mortality in previous studies. Potential mechanisms include arrhythmias or increased risk for thromboembolism, based on platelet activation and/or hypercoagulability.
The aim of this experimental study is to investigate the impact of hypoglycaemia on platelet activation parameters (PAP) during a hyperinsulinaemic hypoglycaemic clamp study. We hypothesize that Hypoglycaemia in patients with T2DM leads to increased platelet activation.
The primary objective is to investigate platelet activation during different levels of hypoglycaemia induced by a stepwise hyperinsulinaemic, hypoglycemic clamp experiment in patients with T2DM.
Active study duration will be 5 days for each study participant. 14 subjects with T2DM without history of cardiovascular events or manifest atherosclerosis will be enrolled. During this monocentric, single arm, open, mechanistic trial platelet activation and recovery at one week after the clamp experiment, changes of pro-atherothrombotic markers during the hypoglycaemic clamp as well as counter regulatory hormone response during the clamp will be investigated.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Graz, Austria, 8036
- Medical University of Graz, Department for Internal Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female aged 18-64 years (both inclusive) at the time of signing informed consent
- Subjects diagnosed with type 2 diabetes (diagnosed regarding world health organization [WHO] criteria) and on stable treatment for a period of 90 days prior to screening with metformin as monotherapy or diet only. Stable is defined as unchanged dose
- Body mass index (BMI) between 20.0 and 35.0 kg/m2 (both inclusive)
- HbA1c between 43 and 64 mmol/mol (6.0% - 8.0%) (both inclusive)
- No use of platelet inhibiting therapy (e.g. aspirin, clopidogrel, ticagrelor, prasugrel)
Exclusion Criteria:
- All other forms of diabetes (type 1 diabetes, gestational diabetes) than type 2 diabetes mellitus
- Treatment with any glucose lowering agent(s) other than metformin in a period of 60 days before screening. An exception is short-term treatment (≤ 7 days in total) with insulin due to intercurrent illness
- Impaired hypoglycaemic awareness determined at the discretion of the investigator
- Medical history of arrhythmia as atrial fibrillation, atrial flutter, atrioventricular dissociation disorders or ventricular arrhythmias
- Previously known cardiovascular disease and / or past cardiovascular events, or past episodes of a congestive heart failure syndrome (NYHA II - NYHA IV)
- Severe hypoglycaemic event requiring third party help in the last 6 months
- Known allergy to human insulin or dextrose solution
- Clinically significant abnormal haematology, biochemistry, lipids, hormones, coagulation or urinalysis
- Uncontrolled hypertension defined as resting blood pressure at screening (after resting for 5 min, measured in sitting position) outside the range of 90-160 mmHg for systolic or 50-100 mmHg for diastolic
- Chronic liver failure with severe liver dysfunction as assessed by the investigator
- Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) levels > 3x upper Limit of normal (ULN)
- estimated Glomerular Filtration Rate (eGFR) <45 ml/min/1,73 m2
- Any musculoskeletal disorders holding back from stay in bed in a lying position during the time of the clamp experiments
- Treatment with beta-blockers, antiarrhythmic agents or neuroleptic drugs
- Active smoker or intake of illicit substances
- Regular intake of nonsteroidal anti-inflammatory drugs (NSAIDs)
- Any mental disorders or psychiatric conditions which may interfere with understanding or conduction of study related procedures
- Females of child bearing potential without adequate contraceptive methods (i.e. sterilisation, intrauterine device, vasectomised partner; or medical history of hysterectomy)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Clamp Arm
All 14 subjects will undergo an Euglycaemic Clamp at Visit 2 as well as a Hyperinsulinaemic/Hypoglycaemic Clamp at Visit 3 with the Intervention of reaching certain plasma glucose levels for blood sampling regarding platelet activity parameters.
Infusion of Dextrose and human soluble insulin (Actrapid) will be used to reach certain plasma glucose levels.
|
All 14 subjects will undergo an euglycaemic clamp at Visit 2 with a plasma Glucose target of 5.5 mmol/L +/- 10% (4 timepoints for platelet activity parameter blood sampling)
All 14 subjects will undergo a hypoglycaemic/hyperinsulinaemic clamp at Visit 3 with 4 timepoints for platelet activity Parameter blood sampling 30 minutes after reaching certain plasma glucose plateaus (5.5 mmol/L; 3.5 mmol/L; 2.5 mmol/L; after recovery again at 5.5 mmol/L)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Platelet Activation Marker Adenosin Diphosphate (%)
Time Frame: Measurement during different levels of hypoglycaemia as well as 1 and 7 days after the clamp experiment
|
Changes in platelet activation measured by light transmittance aggregometry (LTA) on a Chronolog 700 Lumi-Aggregometer based on Adenosin Diphosphate (ADP %) activation. Visit 3, Hyperinsulinaemic/Hypoglycaemic clamp Experiment: Timepoint 0 (Baseline = Plasma Glucose 100mg/dL [5.5mmol/L]) Timepoint 1 (Hypoglycaemia Plateau 1 = Plasma Glucose 63mg/dL [3.5mmol/L]) Timepoint 2 (Hypoglycaemia Plateau 2 = Plasma Glucose 45mg/dL [2.5mmol/L]) Timepoint 3 (Recovery = Plasma Glucose 100mg/dL [5.5mmol/L] Follow up 1 (1 Day after the Clamp Experiment) Follow up 2 (7 +/- 1 day after the Clamp Experiment) |
Measurement during different levels of hypoglycaemia as well as 1 and 7 days after the clamp experiment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quantification of Platelet Function and Activation PAC1CD62PCD63POS (%)
Time Frame: Measurement during different levels of hypoglycaemia as well as 1 and 7 days after the clamp experiment
|
Quantification of platelet activation markers by flow cytometry in unstimulated blood samples (CD62P, CD63 and binding of PAC-1) using a BD LSRFortessa flow cytometer. Hyperinsulinaemic/Hypoglycaemic clamp Experiment: Timepoint 0 (Baseline = Plasma Glucose 100mg/dL [5.5mmol/L]) Timepoint 1 (Hypoglycaemia Plateau 1 = Plasma Glucose 63mg/dL [3.5mmol/L]) Timepoint 2 (Hypoglycaemia Plateau 2 = Plasma Glucose 45mg/dL [2.5mmol/L]) Timepoint 3 (Recovery = Plasma Glucose 100mg/dL [5.5mmol/L] Follow up 1 (1 Day after the Clamp Experiment) Follow up 2 (7 +/- 1 day after the Clamp Experiment) |
Measurement during different levels of hypoglycaemia as well as 1 and 7 days after the clamp experiment
|
Markers of Coagulation Plasminogen Activator Inhibitor-1 (ng/mL)
Time Frame: Measurement during different levels of hypoglycaemia as well as 1 and 7 days after the clamp experiment
|
Effects on coagulation parameter plasminogen activator Inhibitor-1 (PAI-1) measured by Enzyme-linked immunosorbent assays. Visit 3, Hyperinsulinaemic/Hypoglycaemic clamp Experiment: Timepoint 0 (Baseline = PG 100mg/dL [5.5mmol/L]) Timepoint 1 (Hypoglycaemia Plateau 1 = PG 63mg/dL [3.5mmol/L]) Timepoint 2 (Hypoglycaemia Plateau 2 = PG 45mg/dL [2.5mmol/L]) Timepoint 3 (Recovery = PG 100mg/dL [5.5mmol/L] Follow up 1 (1 Day after the Clamp Experiment) Follow up 2 (7 +/- 1 day after the Clamp Experiment) |
Measurement during different levels of hypoglycaemia as well as 1 and 7 days after the clamp experiment
|
Changes in Coagulation Marker Fibrinogen (g/L)
Time Frame: Measurement during different levels of hypoglycaemia as well as 1 and 7 days after the clamp experiment
|
Changes in coagulation marker Fibrinogen, measured on a Behring Coagulation System BCS XP Analyzer. Visit 3, Hyperinsulinaemic/Hypoglycaemic clamp Experiment: Timepoint 0 (Baseline = PG 100mg/dL [5.5mmol/L]) Timepoint 1 (Hypoglycaemia Plateau 1 = PG 63mg/dL [3.5mmol/L]) Timepoint 2 (Hypoglycaemia Plateau 2 = PG 45mg/dL [2.5mmol/L]) Timepoint 3 (Recovery = PG 100mg/dL [5.5mmol/L] Follow up 1 (1 Day after the Clamp Experiment) Follow up 2 (7 +/- 1 day after the Clamp Experiment) |
Measurement during different levels of hypoglycaemia as well as 1 and 7 days after the clamp experiment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Harald Sourij, Medical University of Graz, Division of Endocrinology and Diabetology
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HS-2017-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting
Clinical Trials on Euglycaemic Clamp
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesDenmark, Japan
-
Bispebjerg HospitalUniversity Hospital, Gentofte, Copenhagen; Psychiatric Centre RigshospitaletCompletedHypoglycemia | Cognitive Change | Diabetes Mellitus, Type IIDenmark
-
University Hospital, AntwerpRecruitingInsulin Resistance | Type 1 DiabetesBelgium
-
University of AarhusDanish Diabetes AcademyCompletedType 2 Diabetes | NAFLD - Non-Alcoholic Fatty Liver DiseaseDenmark
-
Assistance Publique Hopitaux De MarseilleCompleted
-
University of HullHull University Teaching Hospitals NHS TrustCompleted
-
Emory UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Liverpool John Moores UniversityLiverpool University Hospitals NHS Foundation Trust; Royal Liverpool University... and other collaboratorsCompleted
-
University of Illinois College of Medicine at PeoriaOSF Healthcare SystemUnknown
-
Albert Einstein College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes | Malnutrition; Diabetes